Hypercoagulability After Immunotherapy with Corynebacterium Parvum in Man

Overview

Journal Blut

Specialty Hematology

Date 1982 Apr 1

PMID 7082858

Citations 2

Authors

J Harenberg

A Baumgartner

D Fritze

R Zimmermann

Affiliations

Soon will be listed here.

Abstract

The effect of an immunotherapy with Corynebacterium parvum on the blood coagulation system was investigated in a randomized trial of 18 patients with metastatic breast cancer. All patients received cytostatic therapy. Additionally, C. parvum was given intravenously on day 15 of the cytostatic cycle (group I) or on day 1 (group II) or not at all (group III). Fibrinopeptide A increased within 2 h after intravenous administration of C. parvum in groups I and II and normalized after 24 h (p less than 0.05). Platelet counts decreased continuously in all treatment groups (p less than 0.05). Prothrombin time, fibrinolytic concentration, factor VIII:C and factor VIIIR:Ag were not affected. The fibrinolytic activity showed a slight but not statistically significant increase after intravenous administration of C. parvum. The data suggest that plasma hypercoagulability is induced or enhanced in man even after small intravenous doses of C. parvum.

Citing Articles

The effects of a combination of cigarette smoking and oral contraception on coagulation and fibrinolysis in human females.

Harenberg J, Staiger C, de Vries J, Weber E, Zimmermann R, Schettler G Klin Wochenschr. 1985; 63(5):221-4.

PMID: 3990165 DOI: 10.1007/BF01731173.

Evaluation of procoagulant activity production and other coagulative functions in cancer patients receiving acid treated Salmonella minnesota R 595 (Re).

Miragliotta G, Di Vagno G, Nappi R, Fumarola D, Jirillo E, Galanos C Eur J Epidemiol. 1988; 4(3):377-81.

PMID: 3181391 DOI: 10.1007/BF00148928.

References

Harenberg J, Zimmermann R, Weber E . Fibrinopeptide A in acute coronary insufficiency. Lancet. 1981; 1(8211):96-7. DOI: 10.1016/s0140-6736(81)90028-3. View

Peuscher F, Cleton F, Armstrong L, van Mourik J, Van Aken W . Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. J Lab Clin Med. 1980; 96(1):5-14. View

Harenberg J, Hepp G, Schmidt-Gayk H . Fibrinopeptide A in human plasma--evaluation of a new radioimmunoassay technique on microliter--plates. Thromb Res. 1979; 15(3-4):513-22. DOI: 10.1016/0049-3848(79)90157-9. View

Mitcheson H, Hilgard P, McCraw A, Castro J . Mechanisms of C. Parvum-induced coagulopathy in mice. Br J Cancer. 1980; 41(1):117-22. PMC: 2010159. DOI: 10.1038/bjc.1980.13. View

Harenberg J, Weber E, Spohr U, Morl H . Is the diurnal increase of fibrinolytic activity influenced by alpha- or beta-adrenergic blockade?. Blut. 1980; 41(6):455-8. DOI: 10.1007/BF01007771. View

Yudelman I, Nossel H, Kaplan K, Hirsh J . Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. Blood. 1978; 51(6):1189-95. View

LAURELL C . Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem. 1966; 15(1):45-52. DOI: 10.1016/0003-2697(66)90246-6. View

Cederholm-Williams S, King A, Allington M, Gill P, Sharp A, Britton B . Coagulation and fibrinolysis during the infusion of Corynebacterium parvum in man. Br J Cancer. 1978; 37(6):1074-7. PMC: 2009647. DOI: 10.1038/bjc.1978.155. View

Chew E, Wallace A . Demonstration of fibrin in early stages of experimental metastases. Cancer Res. 1976; 36(6):1904-9. View

10.

Nossel H, Yudelman I, Canfield R, Butler Jr V, Spanondis K, Wilner G . Measurement of fibrinopeptide A in human blood. J Clin Invest. 1974; 54(1):43-53. PMC: 301523. DOI: 10.1172/JCI107749. View

11.

Lyman G, BETTIGOLE R, Robson E, AMBRUS J, Urban H . Fibrinogen kinetics in patients with neoplastic disease. Cancer. 1978; 41(3):1113-22. DOI: 10.1002/1097-0142(197803)41:3<1113::aid-cncr2820410346>3.0.co;2-d. View

12.

Harenberg J, Haas R, Zimmermann R . Measurement of fibrinopeptide A in patients treated with phenprocoumon. Thromb Haemost. 1981; 45(3):282-4. View

13.

GODAL H, Abildgaard U . Gelation of soluble fibrin in plasma by ethanol. Scand J Haematol. 1966; 3(5):342-50. DOI: 10.1111/j.1600-0609.1966.tb02378.x. View

14.

Donati M, Poggi A . Malignancy and haemostasis. Br J Haematol. 1980; 44(2):173-82. DOI: 10.1111/j.1365-2141.1980.tb01199.x. View

15.

Jones P, Sadler T, Castro J . Effect of Corynebacterium parvum on peripheral blood platelets. Br J Cancer. 1977; 36(6):777-82. PMC: 2025572. DOI: 10.1038/bjc.1977.261. View

16.

Bouma B, Starkenburg A . Dilution of haemophilic plasma used as a reagent in the determination of anti-haemophilic factor A (factor VIII). Haemostasis. 1974; 3(2):94-7. DOI: 10.1159/000214044. View

17.

Mayr A, Senn H, Gallmeier W, Bruntsch U, Becher R, Drings P . [Adriamycin-combination chemotherapy with or without immune stimulation by corynebacterium parvum in metastasizing carcinoma of the breast (author's transl)]. Dtsch Med Wochenschr. 1979; 104(49):1739-43. DOI: 10.1055/s-0028-1129182. View

18.

Zimmermann R, Morl H, Harenberg J . [Urokinase treatment of phlegmasia coerulea dolens (author's transl)]. Dtsch Med Wochenschr. 1979; 104(44):1563-7. DOI: 10.1055/s-0028-1129145. View

19.

Israel L, Edelstein R . Personal experience with Corynebacterium parvum in human cancers. World J Surg. 1977; 1(5):585-95. DOI: 10.1007/BF01556183. View